Andelyn Biosciences

Mayo Pujols, CEO

April 21 | 3:45pm | Gaudi 2 Ballroom

Columbus, OH


In-Person Presentation

Andelyn Biosciences is pioneering solutions that turn hope into reality as a cell and gene therapy CDMO. The company’s capabilities span viral vector process and analytical development, small- to large-scale adherent and suspension-based GMP manufacturing up to 2000L. Having 20+ years of experience with viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting/characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 400+ cGMP clinical batches, Andelyn provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing (early 2022), full quality system/regulatory support, and supply chain vertical integration. Its state-of-the-art 185,000 sq. ft. commercial manufacturing facility will expand capacity across 16+ production suites for customization of new programs and tech transferred programs as of July 2022, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients.

By using this website you agree to accept our Privacy Policy and Terms & Conditions